SCHEMBL5078014

SCHEMBL5078014

COCCN(CCOc1ccc2[nH]c(-c3cc4ccccc4[nH]c3=O)cc2c1)Cc1cccnc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.69
KDM4E B2RXH2 7/20 0.51
HSD17B10 Q99714 6/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
KCNA5 P22460 4/20 0.46
NPSR1 Q6W5P4 2/20 0.45
MAPK1 P28482 1/20 0.45
USP2 O75604 4/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
CHEK1 O14757 1/20 0.43
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5079459 0.92 KDR (0.71) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5082008 0.91 KDR (0.72) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5081988 0.90 KDR (0.77) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5082530 0.88 KDR (0.69) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5082016 0.88 KDR (0.71) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5081966 0.87 KDR (0.70) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5078729 0.87 KDR (0.72) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5076110 0.87 KDR (0.86) KDRKDM4EHSD17B10HPGDCHEK1
SCHEMBL5078715 0.85 KDR (0.72) KDRKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5141013 0.85 KDR (0.77) KDRKDM4EALDH1A1HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080274107-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-11-06 US disclosed
US-7186723-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-03-06 US disclosed
US-6794393-B1 inhibitors of VEGF; angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases; 1H-indole compounds having a fused nitrogen heterocycle amide in the 2-position MERCK & CO., INC. 2004-09-21 US disclosed
US-6306874-B1 ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. MERCK & CO., INC. 2001-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080274107-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KDR 5/4885KDM4E 2200/4885HSD17B10 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.